Peter E Schwartz MD

John Slade Ely Professor of Obstetrics, Gynecology, and Reproductive Sciences; Vice Chair, Gynecology; Section Chief, Gynecologic Oncology

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Ovarian Cancer Program, Early Detection

Education & Training

  • M.D., Albert Einstein College (1966)
  • Resident, Yale-New Haven Hospital , Obstetrics & Gynecology
  • Fellow, MD Anderson Cancer Center, Houston, Texas , Gynecologic Oncology
  • Fellow, Yale University School of Medicine , Obstetrics & Gynecology

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Ovarian, uterine, vaginal, cervical and vulvar cancer; Difficult gynecologic surgery; Screening for ovarian cancer; Gestational neoplasia; Brachytherapy


Board Certifications

  • Gynecologic Oncology, Board Certified (1979)
  • Obstetrics & Gynecology, Board Certified (1973)

Clinical Trials

ConditionsStudy Title
Endometrial Cancer and Corpus UteriA Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (GOG 0258) (CIRB)
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Edit Profile